A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health

Inclusion Criteria:

- Each participant must sign an informed consent form (ICF) indicating that he or she
understands the purpose of and procedures required for the study, is willing to
participate in the study and attend all scheduled visits, and is willing and able to
comply with all study procedures and adhere to the prohibitions and restrictions
specified in this protocol

- Before randomization, a woman must be:

1. Postmenopausal (A postmenopausal state is defined as no menses for 12 months
without an alternative medical cause) and

2. Not intending to conceive by any methods

- In the investigator's clinical judgment, participant must be either in good or stable
health, and not at risk of serious complications from influenza. Participants may have
underlying illnesses such as hypertension, type 2 diabetes, hyperlipoproteinemia, or
hypothyroidism, as long as their symptoms/signs are medically controlled. If they are
on medication for a condition, the medication dose must have been stable for at least
12 weeks (or only small, clinically non-significant changes have been made in the
judgement of the Principal Investigator) preceding vaccination and expected to remain
stable for the duration of the study. Participants will be included on the basis of
physical examination, medical history, vital signs, and 12-lead electrocardiogram
(ECG) performed on Day 1

- From the time of first vaccination through 3 months after the second dose of study
vaccine, participant agrees not to donate blood

- Participant must be willing to provide verifiable identification, have means to be
contacted and to contact the investigator during the study

Exclusion Criteria:

- Participant has acute illness (this does not include minor illnesses such as diarrhea)
or temperature greater than or equal to (>=) 38.0 degree Celsius (ºC) within 24 hours
prior to the first dose of study vaccine; enrollment at a later date is permitted

- Participant has a serious chronic disorder, including severe chronic obstructive
pulmonary disease or clinically significant congestive heart failure, requirement for
supplemental oxygen, end stage renal disease with or without dialysis, clinically
unstable cardiac disease, Alzheimer's disease, or has any condition for which, in the
opinion of the investigator, participation would not be in the best interest of the
participant (for example, compromise well-being) or that could prevent, limit, or
confound the protocol-specified assessments

- Participant has history of malignancy within 5 years before screening (exceptions are
squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or
malignancy, which is considered cured with minimal risk of recurrence)

- Participant has had major surgery (per the investigator's judgment), within 4 weeks
before dosing, or will not have fully recovered from surgery, or has surgery planned
during the time the participant is expected to participate in the study or within 6
months after the final dose of study vaccine

- Participant has chronic active hepatitis B or hepatitis C infection, documented by
hepatitis B surface antigen and hepatitis C antibody, respectively